How big is LAVA Therapeutics NV?

As of Jun 18, LAVA Therapeutics NV has a market capitalization of 34.20 million and reported net sales of 4.99 million with a net profit of -27.95 million over the latest four quarters. The company's shareholder's funds are 27.75 million, with total assets of 80.83 million.

Market Cap: As of Jun 18, LAVA Therapeutics NV has a market capitalization of 34.20 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, LAVA Therapeutics NV reported net sales of 4.99 million and a net profit of -27.95 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 27.75 million, while total assets were reported at 80.83 million.

What does LAVA Therapeutics NV do?

LAVA Therapeutics NV is a micro-cap biotechnology company focused on pharmaceuticals, currently reporting a net profit loss of $3 million and a market cap of $34.20 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -128.56%.

Overview: <BR>LAVA Therapeutics NV operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 34.20 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.57 <BR>Return on Equity: -128.56% <BR>Price to Book: 1.33 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold LAVA Therapeutics NV?

Is LAVA Therapeutics NV overvalued or undervalued?

As of May 17, 2022, LAVA Therapeutics NV is considered a risky investment due to its overvaluation, negative ROE of -128.56%, and poor performance compared to peers and the S&P 500, with a one-year return of -12.5%.

As of 17 May 2022, LAVA Therapeutics NV's valuation grade moved from does not qualify to risky, indicating a shift towards a more cautious assessment. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 1.35 and an EV to EBIT of 0.90, which suggests that the market may be pricing in expectations that are not supported by its earnings performance. Additionally, the ROE is notably negative at -128.56%, further emphasizing the challenges the company faces.<BR><BR>In comparison to its peers, LAVA's valuation ratios are less favorable; for instance, Precision BioSciences, Inc. has a more favorable EV to EBITDA of -0.2328, while Marker Therapeutics, Inc. shows a better EV to EBIT at 0.0342. The stock has underperformed against the S&P 500 over the past year, returning -12.5% compared to the index's 17.14%, reinforcing the notion that LAVA may not be a compelling investment at its current price.

Is LAVA Therapeutics NV technically bullish or bearish?

As of July 24, 2025, LAVA Therapeutics NV shows a mildly bullish technical trend, supported by positive weekly MACD and moving averages, but mixed signals from Bollinger Bands and Dow Theory suggest caution, especially given its recent underperformance against the S&P 500 despite strong year-to-date returns.

As of 24 July 2025, the technical trend for LAVA Therapeutics NV has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages also reflect a mildly bullish stance. However, the monthly Bollinger Bands are bearish, and the Dow Theory shows a mildly bearish position for both weekly and monthly time frames. The KST is bullish on a weekly basis but bearish monthly, and the RSI shows no signal for both time frames.<BR><BR>In terms of performance, LAVA has underperformed the S&P 500 over the past week and month, with returns of -4.55% and -3.29% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, LAVA has significantly outperformed the benchmark with a return of 54.57% compared to the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from other indicators.